All updated as on -
By 2030, the Global Specimen Validity Testing Market (SVT) is anticipated to reach USD 4.18 billion, growing at a 7.9% CAGR from 2023 to 2030.
During the forecast period of 2023–2030, the market for specimen validity testing is expected to grow at a faster rate due to a number of important factors, including the expanding drug screening industry, rising workplace drug testing preferences, an increase in drug abuse cases globally, and rising government spending on drug abuse prevention. The market for specimen validity testing will expand over the projected period as a result of the adoption of point-of-care specimen validity testing, which will provide additional opportunities.
The detection of substitution, adulteration, or dilution in a urine drug screen specimen is done using Specimen Validity Tests (SVT). By evaluating pH, creatinine, and specific gravity (where necessary) and checking for adulterants that may have been introduced to the urine specimen, specimen validity testing can assist assure the accuracy of the test. To be declared legitimate, a urine sample must meet all three of these crucial requirements and fall within the range of typical human pee. The body's acid-base balance is measured by pH, while a substance's specific gravity tells us how dense it is in relation to water. Every urine drug test must include specimen validity testing as a crucial component. Negative effects may emerge from drug level concentrations below the drug metabolite threshold value.
Improved testing methods and more diagnostic facilities for drugs are some important factors anticipated to drive the market and increase the use of high-risk substances worldwide. The public is becoming more aware of the global specimen validity testing industry as a result of the use of illegal substances like marijuana, heroin, cocaine, hallucinogens, and other non-medical alcoholic beverages and psychiatric pharmaceuticals. For the benefit of the populace, the government is also encouraging drug testing programs at work, which will spur revenue growth in the market for specimen validity testing throughout the anticipated time frame. SVT is additionally utilized by law enforcement agencies to protect criminals and suspects by identifying the presence and traces of illicit drugs. It assists law enforcement officials in examining the actions and causes of a certain crime. An increase in the use of illegal drugs is fueling the global specimen validity testing market. The specimen validity testing market is anticipated to grow globally during the forecast period as a result of stringent testing standards and government spending to fight drug addiction.
The use of specimen validity testing may be hampered by the market's abundance of fast drug tests that produce accurate results. Over the course of the projected period, regulatory approval procedures for Rapid Test items are probably going to be time-consuming and expensive, which will limit market growth. Furthermore, point-of-care testing and workplace drug testing methodologies do not align with specimen validity testing, which is anticipated to hamper market growth during the forecast period.
There is a greater need for psychological services in the United States as a result of the continuous stress and uncertainty of COVID-19, but not everyone is experiencing anxiety or depression. Experts claim that there is an increase in the abuse of stimulants and opioids, and psychologists are in a good position to help. According to a report by the American Medical Association, opioid-related mortality increased in more than 40 U.S. states in December 2020, raising persistent worries for those who have substance use disorders. The pandemic accounted for extensive testing in several areas as drug usage surged.
Details about each competitor are provided in the specimen validity testing market competitive landscape. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The aforementioned data points are limited to the companies' market focus on specimen validity testing.
Report Coverage
Global Specimen Validity Testing (SVT) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Specimen Validity Testing (SVT) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Specimen Validity Testing (SVT) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Specimen Validity Testing (SVT) market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Specimen Validity Testing (SVT) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Specimen Validity Testing (SVT) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Puritan Medical Products (U.S.), BD (U.S.), Laboratory Corporation of America Holdings (U.S.), Lucence Health Inc. (Singapore), Hardy Diagnostics (U.S.), BTNX (Canada), Formlabs (U.S.), Medline Industries, Inc. (U.S.), VIRCELL S.L. (Spain), HiMedia Laboratories (India), Titan Biotech (India), McDermott Will & Emery (U.S.), Miraclean Technology Co.,Ltd (China), Starplex Scientific Inc. (Canada), DiaSorin Molecular LLC (U.S.)
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Specimen Validity Testing (SVT) market based on the below-mentioned segments:
Global Specimen Validity Testing (SVT) Market, By Product and Services
Product {Assay Kits, Reagents & Calibrators, Disposables}
Service
Global Specimen Validity Testing (SVT) market, By Drug Class
Laboratory Testing
Rapid/POC Testing
Global Specimen Validity Testing (SVT) Market, By End User
Workplace
Drug Screening
Pain Management
Drug Rehabilitation Centers
Global Specimen Validity Testing (SVT) market, Regional Analysis
During the forecast period of 2023–2030, the market for specimen validity testing is expected to grow at a faster rate due to a number of important factors, including the expanding drug screening industry, rising workplace drug testing preferences, an increase in drug abuse cases globally, and rising government spending on drug abuse prevention. The market for specimen validity testing will expand over the projected period as a result of the adoption of point-of-care specimen validity testing, which will provide additional opportunities.
The detection of substitution, adulteration, or dilution in a urine drug screen specimen is done using Specimen Validity Tests (SVT). By evaluating pH, creatinine, and specific gravity (where necessary) and checking for adulterants that may have been introduced to the urine specimen, specimen validity testing can assist assure the accuracy of the test. To be declared legitimate, a urine sample must meet all three of these crucial requirements and fall within the range of typical human pee. The body's acid-base balance is measured by pH, while a substance's specific gravity tells us how dense it is in relation to water. Every urine drug test must include specimen validity testing as a crucial component. Negative effects may emerge from drug level concentrations below the drug metabolite threshold value.
Improved testing methods and more diagnostic facilities for drugs are some important factors anticipated to drive the market and increase the use of high-risk substances worldwide. The public is becoming more aware of the global specimen validity testing industry as a result of the use of illegal substances like marijuana, heroin, cocaine, hallucinogens, and other non-medical alcoholic beverages and psychiatric pharmaceuticals. For the benefit of the populace, the government is also encouraging drug testing programs at work, which will spur revenue growth in the market for specimen validity testing throughout the anticipated time frame. SVT is additionally utilized by law enforcement agencies to protect criminals and suspects by identifying the presence and traces of illicit drugs. It assists law enforcement officials in examining the actions and causes of a certain crime. An increase in the use of illegal drugs is fueling the global specimen validity testing market. The specimen validity testing market is anticipated to grow globally during the forecast period as a result of stringent testing standards and government spending to fight drug addiction.
The use of specimen validity testing may be hampered by the market's abundance of fast drug tests that produce accurate results. Over the course of the projected period, regulatory approval procedures for Rapid Test items are probably going to be time-consuming and expensive, which will limit market growth. Furthermore, point-of-care testing and workplace drug testing methodologies do not align with specimen validity testing, which is anticipated to hamper market growth during the forecast period.
There is a greater need for psychological services in the United States as a result of the continuous stress and uncertainty of COVID-19, but not everyone is experiencing anxiety or depression. Experts claim that there is an increase in the abuse of stimulants and opioids, and psychologists are in a good position to help. According to a report by the American Medical Association, opioid-related mortality increased in more than 40 U.S. states in December 2020, raising persistent worries for those who have substance use disorders. The pandemic accounted for extensive testing in several areas as drug usage surged.
Details about each competitor are provided in the specimen validity testing market competitive landscape. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The aforementioned data points are limited to the companies' market focus on specimen validity testing.
Report Coverage
Global Specimen Validity Testing (SVT) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Specimen Validity Testing (SVT) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Specimen Validity Testing (SVT) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Specimen Validity Testing (SVT) market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Abbott. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Puritan Medical Products (U.S.), BD (U.S.), Laboratory Corporation of America Holdings (U.S.), Lucence Health Inc. (Singapore), Hardy Diagnostics (U.S.), BTNX (Canada), Formlabs (U.S.), Medline Industries, Inc. (U.S.), VIRCELL S.L. (Spain), HiMedia Laboratories (India), Titan Biotech (India), McDermott Will & Emery (U.S.), Miraclean Technology Co.,Ltd (China), Starplex Scientific Inc. (Canada), DiaSorin Molecular LLC (U.S.) |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Specimen Validity Testing (SVT) Market from 2021 to 2030.
- Market Forecast for Specimen Validity Testing (SVT) Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Specimen Validity Testing (SVT) competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Specimen Validity Testing (SVT)
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Specimen Validity Testing (SVT) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Specimen Validity Testing (SVT) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Abbott. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Puritan Medical Products (U.S.), BD (U.S.), Laboratory Corporation of America Holdings (U.S.), Lucence Health Inc. (Singapore), Hardy Diagnostics (U.S.), BTNX (Canada), Formlabs (U.S.), Medline Industries, Inc. (U.S.), VIRCELL S.L. (Spain), HiMedia Laboratories (India), Titan Biotech (India), McDermott Will & Emery (U.S.), Miraclean Technology Co.,Ltd (China), Starplex Scientific Inc. (Canada), DiaSorin Molecular LLC (U.S.)
Primary Target Market
- Market Players of Specimen Validity Testing (SVT)
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Specimen Validity Testing (SVT) market based on the below-mentioned segments:
Global Specimen Validity Testing (SVT) Market, By Product and Services
Product {Assay Kits, Reagents & Calibrators, Disposables}
Service
Global Specimen Validity Testing (SVT) market, By Drug Class
Laboratory Testing
Rapid/POC Testing
Global Specimen Validity Testing (SVT) Market, By End User
Workplace
Drug Screening
Pain Management
Drug Rehabilitation Centers
Global Specimen Validity Testing (SVT) market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive specimen validity testing svt market market research and competitor analysis for your business to help you develop more profound insights into the specimen validity testing svt market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the specimen validity testing svt market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.